A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Clinical trial NCT04610528 · UNKNOWN
Trial details
- NCT number
- NCT04610528
- Sponsor
- SOLTI Breast Cancer Research Group
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-22
- Primary completion
- 2022-01-30
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.